Notch receptors are highly conserved type I transmembrane glycoproteins that, besides regulating several cellular functions (that is differentiation, proliferation, self renewal and survival), are important in cell fate determination (Artavanis-Tsakonas et al., 1999) . The Notch family consists of one member in Drosophila (Wharton et al., 1985) , two receptors, LIN-12 and GLP-1, in Caenorhabditis elegans (Austin and Kimble, 1989) and four Notch homologs (Notch1-4) in mammals (Weinmaster et al., 1991 (Weinmaster et al., , 1992 Kopan and Weintraub, 1993; Lardelli et al., 1994) . The increasing number of Notch homologs during the evolution process suggests a progressive functional diversification of different Notch proteins, which may be related to their structural differences. In keeping with this hypothesis, although the two Notch homologs in C. elegans can fully substitute for each other in cell fate decisions (Fitzgerald et al., 1993) , the four mammalian Notch proteins display both overlapping and distinct tissue distributions as well as both redundant and distinct functions (Wu and Bresnick, 2007) .
As for the structural organization, all Notch proteins share a similar basic structure. The extracellular domain includes 29-36 epidermal growth factor (EGF)-like repeats, 3 Lin-Notch repeats and 1 transmembrane region. The intracellular region of all Notch orthologs (Notch-IC) contains at least three conserved domains: the membrane-proximal RAM (RBP-jk-associated molecule) domain, seven consecutive ankyrin repeats (ANK domain) and a C-terminal PEST (prolineglutamic acid-serine-threonine) sequence. A complete transactivation domain (TAD) is present only in Notch1 and 2 and is located C-terminal to the ANK repeats (Kurooka et al., 1998; Beatus et al., 2001) .
The Notch3 gene was identified as the third mammalian Notch and was initially described as being expressed in proliferating neuroepithelium (Lardelli et al., 1994) . Despite sharing a similar basic structure with respect to Notch1 and 2, Notch3 displays a number of structural differences. The most obvious is represented by a significantly shorter region that includes the TAD domain, which could in part justify the weak transactivation activity of the Notch3 intracellular domain (Notch3-IC) when compared to Notch1-IC and Notch2-IC (Beatus et al., 2001) . Moreover, additional differences have been reported in the intracellular domain. Indeed, the comparison of different regions of the intracellular domains of Notch1 and Notch3 reveals that amino acid identity is quite high in the ankyrin repeat region (72%) and significantly lower in the RAM domain (41%), in the C-terminal region (21%) and in a region located between the ankyrin repeats and the C-terminal region previously described by Urban Lendahl's group and named RE/AC (50% identity; Beatus et al., 2001) (Figure 1 ). All of these differences could possibly explain the differential ability of Notch3-IC to recruit coactivators and/or corepressors as well as to undergo different conformational changes. Subtle differences have also been reported in the transmembrane domain of Notch3 when compared to other Notch proteins (Kopan and Weintraub, 1993) . We cannot exclude the possibility that these differences may differentially regulate Notch3 intramembranous cleavage, as well as its recruitment to the membrane or its eventual relationship with other membrane-tethered and/or -recruited proteins. Finally, slight differences with respect to Notch1 and Notch2 are also evident in the Notch3 extracellular domain, which specifically lacks the equivalent of EGF repeat 21 and an EGF repeat-sized region that comprises parts of EGF repeats 2 and 3 (Lardelli et al., 1994) .
The current model of canonical Notch signaling suggests that it is triggered when the specific ligand on one cell interacts with the extracellular domain of a Notch receptor on a neighboring cell (Bray, 2006) . This binding induces a conformational change (Vooijs et al., 2004) and triggers two sequential proteolytic cleavages of Notch. The first cleavage, that occurs just external to the transmembrane domain, is catalysed by the tumor necrosis factor a-converting enzyme (TACE), an ADAM (a disintegrin and metalloprotease)-type metalloproteinase (Brou et al., 2000) . This cleavage creates a short-lived transmembrane Notch domain that is recognized by a g-secretase membrane protein complex (De Strooper et al., 1999; Shah et al., 2005) , which releases a soluble cytoplasmic domain of Notch (Notch-IC) from the membrane. Liberated Notch-IC is able to enter the nucleus where it interacts with the CSL transcription factor (CBF-1/RBP-Jk, Suppressor of hairless and Lag-1), and a transcriptional coactivator of the Mastermind-like family (Fortini and ArtavanisTsakonas, 1994; Tamura et al., 1995; Christensen et al., 1996) .
Binding of Notch-IC to CSL depends on a strong interaction between the RAM domain of Notch-IC and the b-trefoil domain of CSL (Tamura et al., 1995; Kurooka et al., 1998) , and on a weak interaction through Notch-IC ankyrin repeats which are specifically able to mediate protein-protein interactions. It has indeed been demonstrated that the ANK domain is important to form a complex with CSL and Mastermind-like1 (MAML1) proteins on DNA (Petcherski and Kimble, 2000; Nam et al., 2006; Lubman et al., 2007) . Finally, the PEST sequence, located near C-terminal end, is involved in negative regulation of protein stability, where it promotes degradation of the intracellular domain of Notch.
Recent observations regarding the crystal structure of the Notch transcriptional activation complex show that the nuclear complex bound to a promoter includes Notch-IC, CSL and MAML1, where the ANK domain of Notch-IC is an integral part of the transcription complex and sustains MAML1 binding (Nam et al., 2006) . The RAM domain of Notch-IC is key for the association between Notch and CSL (Tamura et al., 1995; Barrick and Kopan, 2006) . Such binding determines allosteric changes in the structure that is necessary for the derepression and displacement of corepressors (Barrick and Kopan, 2006; Nam et al., 2006; Wilson and Kovall, 2006; Kovall, 2007) . A recent paper confirmed and extended previous observations of Urban Lendahl's group (Beatus et al., 2001) suggested that the key to the activation potency of all Notch proteins is encoded, in part, within their respective RAM-ANK domains and in part within their C-terminal TAD domains (Ong et al., 2006) . The authors suggest that the different Notch proteins read binding site orientations and distribution on the promoter differently: Notch1 would activate paired CSL-binding sites very efficiently. On the other hand, Notch3 would prefer a single site, but would require additional cis-elements. Moreover, they identify a specialized TAD domain in the Notch3 protein's C-terminal region, which would preferentially activate promoters with zinc-finger binding sites near a CSLbinding site, such as the hes5 promoter (Ong et al., 2006) . Interestingly, Hes5 is activated in vascular smooth muscle cells where Notch3 is preferentially expressed and plays an essential role (Joutel et al., 2000) .
Notch3/ligand interactions: does it exist pairing specificity?
Several Notch ligands have been identified both in vertebrates and invertebrates. They are membranetethered type I proteins and belong to the DSL family (Delta/Serrate (Jagged)/Lag-2). In mammals, five different ligands have been identified: three orthologs are structurally related to Drosophila Delta (Delta-1, -3 and , 1997; Xue et al., 1999; Gale et al., 2004) . Similarly to Notch, DSL ligands are sequentially cleaved by metalloproteinases of the ADAM family (for example ADAM 10/kuz and/or ADAM 17/TACE), resulting in the shedding of an ectodomain fragment (Qi et al., 1999; Ikeuchi and Sisodia, 2003) and undergo proteolitic processing that is mediated by the presenilin/ g-secretase complex to release an intracellular fragment (Ikeuchi and Sisodia, 2003; LaVoie and Selkoe, 2003; Nehring et al., 2005) . The biological function of the ligand-soluble form is controversial, as it has been shown to be able to act as both agonist and antagonist of the Notch receptor (Sakamoto et al., 2002; Li and Baker, 2004) . Moreover, a bidirectional function has been recently suggested for Notch ligands. These ligands have been shown to be able not only to trigger Notch signaling in neighboring cells, but also to signal intrinsically through soluble cytoplasmic domains (C-terminal fragment) that are released by g-secretasedependent cleavage and to activate gene expression (LaVoie and Selkoe, 2003) . Intriguingly, the intracellular domain of Jagged1 has been shown to be able to increase the expression of both Jagged1 itself and Notch3 mRNAs and to include a C-terminal PDZ (PSD-95/DLG/ZO-1) ligand which has been shown to be essential for neoplastic transformation (Ascano et al., 2003) . Moreover, Notch3 seems to be able to reciprocally increase the expression of both the full-length and the cytoplasmic domain of Jagged1 (DB and IS, unpublished data). Interestingly, it has also been shown that after cleavage, the Jagged ectodomain may be shed in the culture medium of cells overexpressing Jagged (LaVoie and Selkoe, 2003) and that soluble forms of Jagged1 may bind Notch receptors with a higher affinity for Notch3 (Shimizu et al., 1999) and may have biological function (Varnum-Finney et al., 1998) .
The molecular mechanism that determines specificity in DSL/Notch binding and signaling is not well defined. In fact, several lines of evidence show that multiple DSL proteins are able to bind to and activate several Notch receptors (Shimizu et al., 1999) . However, more recent reports suggest that some preferential relationships between Notch3 and Jagged-1 may exist, mainly in the context of cancer cell survival and growth (Konishi et al., 2007; Sansone et al., 2007a, b) .
Notch3 in development and disease
Among the four mammalian Notch proteins, Notch3, though showing only subtle structural differences with respect to Notch1 and Notch2, displays a more restricted tissue distribution, being expressed predominantly in vascular smooth muscle (Joutel et al., 2000) , the central nervous system (Lardelli et al., 1994) , certain thymocyte subsets (Felli et al., 1999) and naturally occurring regulatory T cells (Anastasi et al., 2003) . Possibly in keeping with its restricted tissue distribution, targeted deletion of murine Notch3 does not lead to embryonic lethality (Domenga et al., 2004) as is observed with targeted deletion of Notch1 and Notch2 (Swiatek et al., 1994; Hamada et al., 1999) . However, constitutive activation of Notch3, either experimentally induced through generation of transgenic mice or following spontaneous activating genetic mutations, always results in pathology development (Lardelli et al., 1994; Joutel et al., 1996; Bellavia et al., 2000) . Thus, highly stereotyped mutations of the extracellular domain of Notch3 have been associated with cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), an inherited small vessel disease causing stroke and dementia (Joutel et al., 1996) . More recently, the generation of mouse models bearing archetypal CADASIL-Notch3 mutations genetically demonstrated the pathogenicity of such mutations (Lacombe et al., 2005; Monet et al., 2007) . Moreover, Notch3 gene amplification, correlating with Notch3 protein expression, has been identified in ovarian high-grade serous carcinomas (Park et al., 2006) . Similarly, overexpression of Notch3, responsible for increased in vitro tumor cell growth, has been reported in human lung cancers (Konishi et al., 2007) . Constitutive Notch3 activation was also reported to inhibit terminal epithelial differentiation in lungs of transgenic mice (Dang et al., 2003) . Finally, our group has previously reported that enforced expression of Notch3-IC, when targeted to the T-cell lineage, is a potent inducer of T-cell leukemia in mouse models (Bellavia et al., 2000) and that Notch3 overexpression characterizes active and relapsing human T-cell acute lymphoblastic leukemia (T-ALL; Bellavia et al., 2002) .
In summary, similar to other members of the family, disregulated Notch3 signaling (mainly in the form of gain-of-function mutations) underlies human pathologies. However, the molecular mechanisms leading to the development of Notch3-related diseases described above remain elusive. It is also unclear whether the possible relationships between Notch3 and other molecules/ pathways are responsible for the pathogenesis of disease.
Notch3/pTa relationships in T-cell development and leukemogenesis: a paradigm of functional diversity in Notch family
Notch1 and Notch3 receptors have been related to different crucial steps of intrathymic T-cell development (Rothenberg, 2001 ) and experimental evidence, derived from gain-of-function models, has suggested that alterations in both Notch1-and Notch3-signaling pathways are linked to leukemogenesis. Unlike Notch1, Notch3 is preferentially expressed in CD4 À
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À double negative (DN) thymocytes at the CD44 À
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þ DN3 stage, and is downregulated before the transition to Structure and function characterize Notch3
þ double positive (DP) cells (Felli et al., 1999) . The transition across DN to DP is a critical point of thymocyte differentiation and is mediated by pre-T-cell receptor (TCR) signaling and characterized by intense cell proliferation (von Boehmer et al., 1998; Voll et al., 2000) . Expression of constitutively active Notch3 (Notch3-IC) in the T-cell lineage induces an aggressive T-cell leukemia at an early age that is characterized by the sustained expression of pTa, the invariant chain of pre-TCR, and the constitutive activation of nuclear factor (NF)-kB in thymocytes and peripheral T cells (Bellavia et al., 2000) . Increased expression of pTa leads to the constitutive activation of pre-TCR signaling that is induced by Notch3-IC, and is a critical event in T-cell leukemogenesis. In fact, pTa gene disruption in Notch3-IC transgenic mice, obtained by the generation of double-mutant mice (Notch3-IC/ pTa À/À ), disrupts the development of T-cell leukemia (Bellavia et al., 2002) .
The observed constitutive activation of NF-kB seems also to be under the control of the pre-TCR, as Notch3 is able to activate both the canonical and alternative NF-kB pathways in the presence of a functional pre-TCR. It does, however, lose the ability to activate the canonical pathway, which is mainly involved in proliferative events, in the absence of pTa (Vacca et al., 2006) . As Notch3-IC/pTa À/À mice do not develop leukemia, the observations above suggest that the activation of the canonical NF-kB pathway could play a key role in mediating the Notch3's leukemogenic role. However, when the NF-kB canonical pathway was blocked downstream of pre-TCR, through the deletion of protein kinase (PK)Cy, the protein kinase activated by the pre-TCR and directly responsible for the IkB kinase (IKK)b-dependent canonical activation of NF-kB, the incidence of leukemia was only decreased when compared to the abrogation obtained with the deletion of pTa (Felli et al., 2005) . Together, these observations suggest that though the pre-TCR-dependent activation of NF-kB plays a major role in the development of Notch3-induced T-cell leukemia, it alone is not sufficient and that Notch3-sustained pre-TCR signaling is able to activate additional leukemogenic signals.
It is known that Ikaros null mice, similar to what observed in Notch3-IC transgenic mice, develop an aggressive T-cell leukemia that is dependent on pre-TCR/TCR signaling (Winandy et al., 1995) . Thus, targeting of Ikaros by Notch3 could potentially represent an additional and possibly specific hit, with respect to the activation of NF-kB, necessary for the development and maintenance of T-cell leukemia. In keeping with this, thymocytes and lymphoma cells from Notch3 transgenic mice display an inappropriate expression of non-DNA binding Ikaros isoforms (IK-DN), previously reported in a number of human acute lymphoblastic leukemias, whereas the deletion of pTa prevents the altered expression pattern of Ikaros isoforms (Bellavia et al., 2007) . Moreover, transient transfection experiments demonstrated that only in cells with a functional pre-TCR, Notch3 was able to unequivocally alter the Ikaros isoform expression pattern, generating an increased expression of dominant-negative Ikaros isoforms (IK-DN) (Bellavia et al., 2007) . Notably, Notch1-IC was not able to affect the Ikaros isoform expression pattern in cells bearing a functional pre-TCR or in cells devoid of it. This observation, for the first time, clearly highlights a specific role for Notch3 that is nonredundant with respect to Notch1 in affecting a pathway specifically involved in the development of T-cell leukemia (Bellavia et al., 2007) .
Furthermore, according to a model previously proposed by Beverly and Capobianco (2003) the pathogenetic meaning of the Notch3-induced altered pattern of Ikaros isoforms deals with the ability of a Notch3-triggered transcriptional complex to drive a significant activation of the pTa promoter by binding the same core sequence present in the consensus DNA binding of Ikaros (Bellavia et al., 2007) . Notch3, by increasing the expression of short non-DNA-binding isoforms of Ikaros, may derepress the physiological block of the transcriptional activation of pTa sustained by Ikaros, thus resulting in the reinforcement of pTa expression.
Together, our previous and more recent observations (Bellavia et al., 2000 (Bellavia et al., , 2007 Talora et al., 2003) suggest that Notch3 may exert its effect on pTa transcription through two different ways: a direct mechanism in which Notch3 is able to drive a strong transcriptional activity of the pTa promoter, and an indirect one, in which Notch3 is able to remove the Ikaros full-length inhibitory effect by positively regulating the generation of Ikaros non-DNA-binding isoforms.
As an additional mechanism leading to the increased expression of pTa, Notch3 was specifically able to increase the expression of the RNA-binding protein HuD, which is known to be able to regulate both RNAalternative splicing and RNA stability (Bellavia et al., 2007) . In transient transfection experiments, it has been shown to induce an increase of Ikaros non-DNA binding, spliced isoforms. Notably, the mechanism through which Notch3, and not Notch1, regulates a HuD overexpression also seems to be pre-TCR dependent. Indeed, in Notch3-IC/pTa À/À double-mutant mice, Notch3 activation was not able to induce a detectable HuD expression or an imbalance in Ikaros alternative splicing. Rather, the absence of HuD might be the cause of reduced Ikaros pre-mRNA stability, as we observed a decrease in Ikaros full-length transcripts in Notch3-IC/ pTa À/À double-mutant mice with respect to Notch3-IC transgenic and wild-type mice (Bellavia et al., 2007) .
Overall, the observations above strongly suggest a molecular model that reveals direct crosstalk among Notch3, Ikaros and pTa/pre-TCR signaling, which involves the HuD protein, for the first time, as a regulator of T-cell differentiation and leukemogenesis.
Conclusions and perspectives
As the first observations reporting that activating mutations and epigenetic overexpression of Notch3 were specifically observed in CADASIL and human Structure and function characterize Notch3 D Bellavia et al T-ALL respectively, an increasing number of reports suggest a specific and crucial role for Notch3 in the development and maintenance of different cancers.
The strict requirement of cooperation with pre-TCR signaling that is observed in T-cell leukemogenesis, together with the intersection of Notch3 with important oncogenic pathways such as NF-kB, Ikaros and E2A (Talora et al., 2003) , suggest that transcriptional activity alone may not reflect the full function of Notch3. Rather it could work like a catalytic agent, able to allow the integration of a number of pathways at different levels. Indeed, Notch3 is active at the nuclear level, where it regulates transcription of pTa (Talora et al., 2003; Bellavia et al., 2007) , as well as that of other target genes (that is Hes5; Ong et al., 2006) . It can work at the cytoplasmic level, where it directly interacts with IkB kinase (IKK)a and differentially regulates the activity of canonical and alternative NF-kB pathways (Vacca et al., 2006) . Moreover, it has been recently reported that, due to the specific features of its N-terminal sequence, increased expression of the Notch3 protein may inhibit proteasome function, thus resulting in accumulation of Notch3 itself and possibly other proteins (Zhang et al., 2007) . Finally, Notch3 is active at the cell membrane, where it is able to recruit, by direct physical interaction, PKCy (Felli et al., 2005) , as well as pTa and other proteins known to be recruited to the immunological synapse (S Cemerski and I Shaw, in preparation), possibly participating to its generation, which represents the hallmark of T-cell activation (Cemerski and Shaw, 2006) .
The data reported in this review delineate a complex and incomplete picture of the relationship between Notch3 and other signaling pathways, which characterize Notch3 function, influence its activation outcome and are often cooperative in neoplastic transformation (Figure 2 ). Although increasing evidence supports structural and functional specificity of Notch3 with respect to the other members of Notch family, we cannot ignore the existence of redundancy between different Notch receptors and in particular, between Notch3 and Notch1 with respect to T-cell leukemogenesis. New insights will certainly be revealed by specific inhibitors of individual Notch receptors. These include highly specific anti-Notch3 antibodies that appear to mimic or inhibit certain effects of DSL ligands on Notch3-bearing cells, thus regulating Notch3 activation (Li et al., 2008) . Given that different Notch receptors are associated with different human diseases, further characterization of specific roles, as well as of structural specificities and/or ligand/receptor pairing specificities are likely to have broad experimental and therapeutic impact. 
